Aclaris Therapeutics Reports Q3 2026 Financial Results Exceeding Estimates
Aclaris Therapeutics (ACRS) reported third-quarter financial results that surpassed analyst expectations for both earnings and revenue. The company posted a GAAP EPS of -$0.12, which outperformed estimates by $0.04, and recorded total revenue of $1.48 million, beating projections by $0.25 million. Despite the beat, the company experienced a significant year-over-year decline in top-line performance. Total revenue fell to approximately $1.5 million in Q3 2026 from $3.3 million in Q3 2025, representing a 55.2% decrease. The results highlight a period of contraction in revenue alongside improved bottom-line management relative to consensus forecasts.
Tickers: $ACRS
Topics: earnings beat GAAP EPS revenue decline